In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Making Asset Acquisition Frictionless Via Digital Marketplace and AI

Executive Summary

Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.    

As biopharma companies look to bolster their pipelines, finding a promising asset takes time and meticulous due diligence. An Israeli start-up, 9xchange, is trying to take some of the friction out of the acquisition process through a digital marketplace where buyers are matched with sellers, and vice versa: a dating app for the biopharma industry. 

In this episode of the In Vivo podcast, 9xchange CEO Anat Naschitz talks about the spark that led her to found the company, how it operates and the importance of "liberating and democratizing" sophisticated technologies. 

Joining for the podcast is Matthew Fujisawa, SVP, strategy and corporate development at BenevolentAI Limited, to talk about the company's involvement in the 9xchange marketplace, how BenevolentAI is applying its AI tools to identify opportunities for drug repurposing and indication expansion and how the partnership represents an expansion of BenevolentAI's business and growth strategy.  




0:00 Intro

1:30 Anat Naschitz, CEO of 9xchange, on her journey and founding the company

3:30 Matthew Fujisawa, SVP, strategy and corporate development, BenevolentAI on his background and the BenevolentAI platforms

6:00 How 9exchange addresses deficiencies in the asset acquisition process

9:00 How BenevolentAI is leveraging its technologies to identify drug repurposing and indication expansion opportunities on 9xchange

12:50 9xchange participants, successes and business model

16:00 BenevolentAI's revised strategic plan and AI in drug R&D

19:00 On"liberating and democratizing AI" 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts